How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about nivolumab plus ipilimumab

Anticipated marketing authorisation indication

2.1

Nivolumab (Opdivo, Bristol-Myers-Squibb) with ipilimumab (Yervoy, Bristol-Myers-Squibb) is indicated for the 'first-line treatment of unresectable or metastatic colorectal cancer' in 'adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer'.

Price

2.3

Nivolumab costs £2,633 for a 240 mg vial and ipilimumab costs £3,750 for a 50 mg vial (excluding VAT; BNF online accessed January 2025).

2.4

The company has a commercial arrangement. This makes nivolumab plus ipilimumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence.